Last reviewed · How we verify
timolol maleate and dorzolamide hydrochloride
This combination reduces intraocular pressure by decreasing aqueous humor production (timolol via beta-adrenergic blockade) and increasing aqueous humor outflow (dorzolamide via carbonic anhydrase inhibition).
This combination reduces intraocular pressure by decreasing aqueous humor production (timolol via beta-adrenergic blockade) and increasing aqueous humor outflow (dorzolamide via carbonic anhydrase inhibition). Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | timolol maleate and dorzolamide hydrochloride |
|---|---|
| Also known as | Cosopt PF |
| Sponsor | University of Florida |
| Drug class | Beta-adrenergic antagonist and carbonic anhydrase inhibitor combination |
| Target | Beta-2 adrenergic receptor (timolol); carbonic anhydrase II (dorzolamide) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Timolol maleate is a non-selective beta-adrenergic antagonist that decreases aqueous humor secretion by the ciliary body. Dorzolamide hydrochloride is a topical carbonic anhydrase inhibitor that reduces aqueous humor production and may enhance outflow. Together, these complementary mechanisms provide additive intraocular pressure reduction.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Ocular irritation or discomfort
- Blurred vision
- Tearing
- Bitter taste
- Headache
- Systemic beta-blockade effects (bradycardia, bronchospasm in susceptible patients)
Key clinical trials
- Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Stop Retinal Ganglion Cell Dysfunction Study (PHASE3)
- Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (PHASE4)
- PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM) (PHASE3)
- Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety (PHASE4)
- How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure? (PHASE4)
- A Randomized, Open-label, Active-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-angle Glaucoma or Ocular Hypertension (PHASE2)
- Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: